Geron Corporation (GERN)

Market Cap	1.11B -3.9%
Revenue (ttm)	183.88M +138.8%
Net Income	-83.50M
EPS	-0.13
Shares Out	640.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,091,711
Open	1.740
Previous Close	1.750
Day's Range	1.720 - 1.840
52-Week Range	1.040 - 2.010
Beta	0.67
Analysts	Hold
Price Target	2.17 (+24.71%)
Earnings Date	May 6, 2026

About GERN

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clini...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 30, 1996
• Employees: 258
• Stock Exchange: NASDAQ
• Ticker Symbol: GERN
• Website: https://www.geron.com

Financial Performance

In 2025, Geron's revenue was $183.88 million, an increase of 138.83% compared to the previous year's $76.99 million. Losses were -$83.50 million, -52.17% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for GERN stock is "Hold." The 12-month stock price target is $2.17, which is an increase of 24.71% from the latest price.

Price Target

$2.17

(24.71% upside)

Analyst Consensus: Hold